Semaglutide's Nonarteritic Anterior Ischemic Optic Neuropathy Risk Systematically Assessed in Multiple Reviews.
Re: Liu et al.: Rate and risk of nonarteritic anterior ischemic optic neuropathy with semaglutide use for diabetes and weight loss: a systematic review and meta-analysis (Ophthalmology 2026;133;589-598).
Abstract
Multiple systematic reviews and meta-analyses investigate the rate and risk of nonarteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide use for diabetes and weight loss.
TitrateLab articles covering Semaglutide
Written by TitrateLab, separately from the study summarized above.
